Human neutrophil oxidative response and phagocytic killing of clinical and laboratory strains of Enterococcus faecalis.
Many clinical isolates of Enterococcus faecalis produce a hemolysin/bacteriocin that is plasmid mediated. Recent human epidemiologic studies and animal research suggest that this hemolysin/bacteriocin may enhance the pathogenicity of hemolysin-producing enterococci compared with non-hemolysin-producing strains. These studies determined that clinical strains that produce hemolysin/bacteriocin differed from non-hemolysin-producing clinical and laboratory strains in their ability to induce the production of reactive oxygen intermediates in human peripheral blood neutrophils and in their susceptibility to phagocytic killing in vitro. The induction of superoxide anion generation by neutrophils was demonstrated to be directly proportional to the presence of the hemolysin/bacteriocin plasmid and was transferable to a non-hemolysin-producing laboratory strain by transconjugation. The presence of the plasmid, however, did not effect killing by phagocytic cells in vitro. It is proposed that hemolysin/bacteriocin-producing strains of enterococcus may be more pathogenic due to reactive oxygen product-induced tissue injury in vitro.